BioMarin Pharmaceutical, Inc.

( )
BMRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.17%72.130.0%$2376.77m
NVAXNovavax, Inc. 0.00%178.51251.8%$1337.92m
SRNESorrento Therapeutics, Inc. 9.19%20.551.5%$982.27m
GILDGilead Sciences, Inc. 0.72%69.001.0%$568.33m
AMGNAmgen, Inc. -1.05%238.171.3%$477.09m
BNTXBioNTech SE 2.30%75.650.0%$406.81m
REGNRegeneron Pharmaceuticals, Inc. -1.93%608.242.7%$403.31m
VRTXVertex Pharmaceuticals, Inc. -1.56%268.731.9%$369.46m
BIIBBiogen, Inc. -1.78%300.261.6%$363.67m
ILMNIllumina, Inc. -0.65%353.353.5%$342.14m
VXRTVaxart, Inc. 4.20%9.790.0%$308.62m
EBSEmergent BioSolutions, Inc. -0.19%130.416.4%$188.70m
IBIOiBio, Inc. 3.53%3.810.2%$172.38m
ALXNAlexion Pharmaceuticals, Inc. -1.36%101.882.0%$166.53m
SGENSeattle Genetics, Inc. -1.71%157.706.2%$160.68m

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.